Cardiology (all articles)
RCT | New defibrillation strategies increased the rates of survival to hospital discharge in patients with refractory ventricular fibrillation.
8 Nov, 2022 | 12:27h | UTCDefibrillation Strategies for Refractory Ventricular Fibrillation – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: “Double shock” from two defibrillators could save more lives – Heart & Stroke
Commentary on Twitter
In a trial involving patients with refractory ventricular fibrillation, double sequential external defibrillation or vector-change defibrillation improved survival as compared with standard defibrillation. #AHA22 https://t.co/2l2t9iGnwq pic.twitter.com/SzVU93OsrX
— NEJM (@NEJM) November 6, 2022
RCT | Rapid up-titration of guideline-directed medical therapies for acute heart failure reduced readmissions and deaths.
8 Nov, 2022 | 12:24h | UTCSafety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial – The Lancet (free registration required)
News Release: Maximizing heart failure meds within 2 weeks reduced risk of hospital readmission, death – American Heart Association
Commentary: STRONG-HF: Rapid Uptitration of GDMT After Acute HF Pays Dividends – TCTMD
Review | Management of heart failure with reduced ejection fraction.
8 Nov, 2022 | 12:17h | UTCManagement of heart failure with reduced ejection fraction – Heart
RCT | After an out-of-hospital cardiac arrest, fever prevention for 36 vs. 72 hours resulted in similar outcomes.
8 Nov, 2022 | 12:23h | UTCDuration of Device-Based Fever Prevention after Cardiac Arrest – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In this trial involving patients after out-of-hospital cardiac arrest, fever prevention for 36 or 72 hours did not result in different percentages of patients dying or having severe disability or coma. #AHA22 https://t.co/Cx6x4RfqCE pic.twitter.com/vGSb0iVISN
— NEJM (@NEJM) November 6, 2022
Review | Targeted temperature management in postresuscitation care after incorporating results of the TTM2 Trial.
8 Nov, 2022 | 12:09h | UTCRelated:
Temperature Control After In-Hospital Cardiac Arrest: A Randomized Clinical Trial – Circulation
Hypothermic versus Normothermic Temperature Control after Cardiac Arrest – NEJM Evidence
ERC-ESICM guidelines on temperature control after cardiac arrest in adults – Intensive Care Medicine (if the link is paywalled, try this one)
Review | Oral anticoagulant use in patients with atrial fibrillation and chronic kidney disease.
8 Nov, 2022 | 12:02h | UTC
Cohort Study | Menstrual cycle regularity and length across the reproductive lifespan and risk of cardiovascular disease.
8 Nov, 2022 | 11:54h | UTCCommentary: Irregular, Long Menstrual Cycles Up Risk for Cardiovascular Disease – HealthDay
Commentary on Twitter
Irregular and long menstrual cycles across a woman’s reproductive lifespan may identify women with a higher risk of cardiovascular disease, even after accounting for established CVD risk factors. #OAResearch #OAWeek https://t.co/BxNveNAqg5
— JAMA Network Open (@JAMANetworkOpen) October 29, 2022
RCT | In patients with CKD (eGFR 20-45 mL/min per 1.73 m2), Empagliflozin reduced the risk of progression of kidney disease.
7 Nov, 2022 | 12:56h | UTCEmpagliflozin in Patients with Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: EMPA-KIDNEY supports SGLT2 inhibition for chronic kidney disease – medwire News
Video Summary: EMPA-KIDNEY results: Empagliflozin reduces kidney disease progression and cardiovascular deaths
Commentary on Twitter
In this trial involving patients with chronic kidney disease, empagliflozin resulted in a lower risk of disease progression or death from cardiovascular causes than placebo. #KidneyWk https://t.co/HFgzPgrRFx pic.twitter.com/EPU6Rl14F1
— NEJM (@NEJM) November 4, 2022
RCT | Triglyceride lowering with Pemafibrate fails to reduce CVD risk in patients with Type 2 DM and hypertriglyceridemia.
7 Nov, 2022 | 12:54h | UTCTriglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk – New England Journal of Medicine (link to abstract – $ for full-text)
News Releases:
Commentaries:
Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT – TCTMD
Commentary on Twitter
In a randomized trial, the incidence of cardiovascular events was not lower in patients with diabetes, HTG, and low HDL cholesterol levels who received pemafibrate, although TG, VLDL cholesterol, remnant cholesterol, and Apo C-III levels decreased. #AHA22 https://t.co/bNtIAwWTX0 pic.twitter.com/yWaTWarlsv
— NEJM (@NEJM) November 5, 2022
RCT | Chlortalidone and Hydrochlorothiazide resulted in similar reductions of CVD in older patients with hypertension.
7 Nov, 2022 | 12:50h | UTCNews Release (not published yet): No difference in heart outcomes found in use of two diuretics to treat blood pressure – American Heart Association
Commentaries:
In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE – TCTMD
Diuretic Comparison Project – DCP – American College of Cardiology
RCT | Intravenous iron did not significantly reduce hospital admissions in patients with heart failure and iron deficiency.
7 Nov, 2022 | 12:48h | UTCCommentaries:
IRONMAN Misses but Lends Support to IV Iron Repletion in HF – TCTMD
RCT | Discontinuing RAS inhibitors in patients with advanced CKD did not result in a slower decline in eGFR.
4 Nov, 2022 | 13:55h | UTCRenin–Angiotensin System Inhibition in Advanced Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In this randomized trial, the discontinuation of renin–angiotensin system inhibitors in patients with advanced chronic kidney disease did not lead to a significant between-group difference in the long-term rate of decline in the eGFR. #KidneyWk https://t.co/81EIwG5FQ0 pic.twitter.com/nHNmzlPbHV
— NEJM (@NEJM) November 3, 2022
M-A | Blood pressure lowering and prevention of dementia.
4 Nov, 2022 | 13:46h | UTCNews Release: Best evidence yet that lowering blood pressure can prevent dementia – George Institute for Global Health
Commentary: Meta-Analysis Shows Decrease in Dementia Risk With HTN Treatment – HealthDay
Cohort Study | Low Apgar score and asphyxia complications at birth and risk of longer-term cardiovascular disease.
4 Nov, 2022 | 13:31h | UTCNews Release: Oxygen deprivation at birth could increase risk of cardiovascular disease – Karolinska Institutet
Review | Differing strategies for sudden death prevention in hypertrophic cardiomyopathy.
4 Nov, 2022 | 13:28h | UTCDiffering strategies for sudden death prevention in hypertrophic cardiomyopathy – Heart
2022 ACC/AHA Guideline for the diagnosis and management of aortic disease.
3 Nov, 2022 | 14:21h | UTCNews Release: ACC, AHA Issue Aortic Disease Guideline – American Heart Association
Cross-Sectional Study | Prevalence of and factors associated with high blood pressure among adolescents in India.
3 Nov, 2022 | 13:57h | UTCInvited Commentary: Prevalence of High Blood Pressure Among Youth in India and Association With Future Cardiovascular Disease – JAMA Network Open
Commentary on Twitter
1 in 3 adolescents in India have high BP, which is is associated with the trifecta of overweight/obesity, high blood sugar, high blood lipids, and can be prevented. #OAResearch https://t.co/i2Cth5ol2T
— JAMA Network Open (@JAMANetworkOpen) October 31, 2022
RCT | Effect of high-intensity interval training in patients with atrial fibrillation.
3 Nov, 2022 | 13:53h | UTC
Commentary from the author on Twitter (thread – click for more)
🎃Trick or treat (we hope the latter):
Our RCT exploring HIIT vs. MICT in patients with #afib is now online in @JAMANetworkOpen.
HIIT was not superior to MICT. Both effective & safe options to improve physical & mental health.
(1/4)
— Jennifer Reed (@DrJenniferReed) October 31, 2022
Under a CC-BY License License
Cohort Study | Association of sinoatrial node radiation dose with atrial fibrillation and mortality in patients with lung cancer.
3 Nov, 2022 | 13:39h | UTCAssociation of Sinoatrial Node Radiation Dose With Atrial Fibrillation and Mortality in Patients With Lung Cancer – JAMA Oncology (link to abstract – $ for full-text)
Commentaries:
Incidental sinoatrial node irradiation may increase AF risk in lung cancer – medwire News
Commentary on Twitter
Incidental irradiation to the sinoatrial node may cause new-onset #AtrialFibrillation & decrease overall survival in patients with #LungCancer receiving concurrent #chemoradiotherapy. https://t.co/hPVSnhp11R #RadOnc #LCSM
— JAMA Oncology (@JAMAOnc) September 27, 2022
Observational study suggests Apixaban for AF is associated with a lower risk of GI bleeding vs. other DOACs.
3 Nov, 2022 | 13:32h | UTCComparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation: A Multinational Population-Based Cohort Study – Annals of Internal Medicine (link to abstract – $ for full-text)
News Release: Best blood thinner for minimizing bleeding risk identified – University College London
Commentary: GI Bleeding Lower With Apixaban Versus Other DOACs in A-Fib – HealthDay
ACCP Guideline | Perioperative management of antithrombotic therapy.
1 Nov, 2022 | 12:18h | UTCExecutive Summary: Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline – CHEST
Commentary on Twitter
2022 guideline for perioperative management of VKAs, heparin bridging, DOACs & antiplatelets
Pts requiring elective surgery, in general,🛑💊 before surgery
👉VKAs 3-5d
👉DOACS 1-2d
👉P2Y12 receptor inhibitors 3-7d✅drug specificshttps://t.co/RYNrEOovRe @SCCM_Surgery @SCCM_CPP— Lauren R. Sorce, PhD, RN, CPNP-AC/PC, FAAN, FCCM (@SCCMPresident) August 26, 2022
M-A | Safety and efficacy of interrupting dual antiplatelet therapy one month following percutaneous coronary intervention.
1 Nov, 2022 | 12:14h | UTC
Commentary on Twitter
Interrupting DAPT after 1 month post PCI:
Meta-analysis of 4 RCTs, >25000 pts
Events between 31days and 1yr:
Less bleeding (1.1 vs 1.5%) but no difference in death (1.3 vs 1.6%), MI (1.4 vs 1.2%), ST (0.3 vs 0.2%) or stroke (0.5 vs 0.6%) https://t.co/rdNgCg032B #cardiotwitter pic.twitter.com/yLWREcDzYe— Heeraj Bulluck (@DrHBulluck) October 30, 2022
Under a http://creativecommons.org/licenses/by/4.0/ license
M-A | The success rate of cardioversion for AF was similar between anterior-posterior vs. anterior-lateral electrodes position.
1 Nov, 2022 | 12:09h | UTC
Cohort Study | Distinguishing Type 1 from Type 2 myocardial infarction by using CT coronary angiography.
1 Nov, 2022 | 12:03h | UTC
Cohort Study | Pre-eclampsia is associated with increased risk of premature-onset obstructive coronary artery stenosis.
1 Nov, 2022 | 12:02h | UTCSeverity of obstructive coronary artery stenosis after pre-eclampsia – Heart
Related:
AHA Scientific Statement | Adverse Pregnancy Outcomes and Cardiovascular Disease Risk
Cohort Study: Preeclampsia and Cardiovascular Disease
All Hypertensive Disorders of Pregnancy Increase the Risk of Future Cardiovascular Disease
Gestational Hypertension and Future Risk of Cardiovascular Disease